RESPIFERON

As part of the REVIDA Chair, an article highlighting the use of the Type-I Interferon response as a universal marker for respiratory viral infections was recently accepted by the eBioMedicine journal. Titled “Advancing Respiratory Virus Diagnostics: Integrating the Nasal IFN-I Score for Improved Viral Detection,” this article presents a study conducted on 788 nasopharyngeal samples. The findings demonstrate the strong discriminative power of the Type-I Interferon score in distinguishing viral respiratory samples from those not-infected, identified by first-line tests, which detect the three most common viruses (RSV, SARS-CoV-2, and influenza). Furthermore, our test revealed that in 94% of cases, the Type-I Interferon score successfully identified viral samples missed by frontline tests but confirmed by second-line tests (multiplex test allowing the identification of a broader panel of viruses or bacteria) or viral metagenomics. These results will be validated on a larger scale through various studies conducted under the REVIDA Chair.

M. Mommert-Tripon et al., « Advancing respiratory virus diagnostics: integrating the nasal IFN-I score for improved viral detection », eBioMedicine, vol. 110, p. 105450, déc. 2024, doi: 10.1016/j.ebiom.2024.105450